TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Disc Medicine
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Disc Medicine reported promising results from its Phase 2 trial of DISC-0974 for treating anemia in myelofibrosis patients, demonstrating substantial hematologic responses across different patient subgroups and transfusion statuses.

Insights
GOOGL   positive

Strong cloud revenue growth (34% YoY), profitable cloud business, top-performing AI model, trading at attractive valuation, and significant stock price recovery


IRON   positive

Presented strong clinical trial results showing meaningful anemia responses, reduced transfusion burden, and potential for addressing an unmet medical need in myelofibrosis treatment